Core Viewpoint - Sanofi Pharmaceutical (01530) shares rose over 6%, currently up 6.26% at HKD 32.58, with a trading volume of HKD 413 million [1] Group 1: Clinical Development - Sanofi Pharmaceutical announced Phase 2 clinical study data for 707 combination chemotherapy for 1L NSCLC at the 2025 STIC conference [1] - Pfizer has outlined a global clinical strategy for 707, actively advancing its clinical development after reaching an agreement with Sanofi Pharmaceutical [1] - Pfizer's second wave development plan is expected to add 10 new indications and over 10 novel combination schemes by the end of 2026 [1] Group 2: Financial Performance - Guosen Securities reported that the company is rapidly advancing its innovative drug clinical trials and has completed significant external licensing transactions, maintaining steady growth [1] - Following the successful licensing of 707, the profit forecast has been raised, with expected net profits for 2025-2027 at CNY 9.955 billion, CNY 2.875 billion, and CNY 3.212 billion respectively [1] - The core products of Sanofi Pharmaceutical are progressing rapidly in global clinical development, maintaining an "outperform the market" rating [1]
三生制药现涨超6% 辉瑞将707列为核心管线 计划启动多项临床研究